This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARHGEF9 / Rho guanine nucleotide exchange factor 9 · IHC design guide
Design Immunohistochemistry for ARHGEF9
Plan ARHGEF9 chromogenic IHC in paraffin sections using the reported cytoplasmic staining in CNS tissue, including Purkinje cells and neuropil (HPA tissue IHC). This guide covers tissue selection, staining controls and interpretation of cell-specific signals.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARHGEF9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic CNS staining in Purkinje cells and neuropil (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Hippocampal glial cells may be unstained (HPA tissue IHC) | |
| Regulation | No staining-relevant regulation specified (UniProt) | |
| Isoform / epitope | 3 isoforms; epitope coverage is unspecified (UniProt; datasheet) |
Section 1
Recommended ARHGEF9 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet) with a published mouse brain paraffin-section protocol (PMC6066644).
| Sample | Paraffin-embedded human lung carcinoma tissue; fixative not specified (datasheet A06931-1) |
| Fixation | Image fixative and duration unreported (datasheet A06931-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-ARHGEF9, 1:100 - 1:300 (datasheet A06931-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARHGEF9-positive staining in glandular cells of adrenal gland (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in several tissue, most abundant CNS. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 heat retrieval (page antigen-retrieval setting; PMC6066644), then optimize for the tissue and fixation used.
Section 2
What Is the Expected ARHGEF9 Staining Pattern?
ARHGEF9 is cytoplasmic and associated with the postsynaptic density (UniProt O43307); it has no transmembrane segment (UniProt O43307 topology). In paraffin section IHC, expect cytoplasmic staining in Purkinje cells and staining of cerebral cortical neuropil, both reported at medium intensity (HPA tissue IHC). HPA rates its tissue staining Approved, with external verification pending (HPA tissue IHC).
| Cytoplasmic signal in cerebellar Purkinje cells and staining in cortical neuropil. | This matches two medium intensity observations in CNS tissue (HPA tissue IHC). Interpret neuropil staining by region and structure; it does not identify a particular cell type on its own (general IHC practice). |
| Predominantly nuclear staining, with little cytoplasmic signal. | A predominantly nuclear pattern conflicts with the reported cytoplasmic location and postsynaptic density association (UniProt O43307; HPA subcellular ICC-IF). Check the no-primary control and detection background before assigning this pattern to ARHGEF9 (general IHC practice). |
| Strong signal in a cell population recorded as not detected. | Alveolar cells in lung and germinal center cells in lymph node are reported as not detected (HPA tissue IHC). Check the exact cell population: staining outside it does not contradict that observation. Within it, consider cross-reactivity or endogenous chromogenic activity (general IHC practice). |
| Diffuse color across cells, stroma, or the whole section. | This lacks the cell and compartment pattern reported for ARHGEF9 (HPA tissue IHC; UniProt O43307). Background from detection reagents, inadequate blocking, or excessive primary antibody is possible; a no-primary section helps distinguish detection background (general IHC practice). |
| No signal in Purkinje cells of an interpretable cerebellar section. | Purkinje cells show medium staining in the HPA reference (HPA tissue IHC). First verify that these cells are present, then review the antibody's IHC validation, detection controls, and run conditions; a blank section alone cannot establish absent protein (general IHC practice). |
💡Expected ARHGEF9 appearanceCall a result positive when cytoplasmic Purkinje cell staining or cortical neuropil staining is discernible at approximately medium intensity (HPA tissue IHC; UniProt O43307); isolated nuclear or widespread structure-free color warrants a background check (general IHC practice).
| Cell and tissue choice | Cerebellar Purkinje cells and cortical neuropil offer documented medium signal; hippocampal glial cells are listed as not detected (HPA tissue IHC). Compare the specified cells, not whole tissues, when choosing controls (general IHC practice). |
| Antibody validation | One listed rabbit antibody has Approved IHC status; its external verification remains pending (HPA HPA035419; HPA tissue IHC). This supports a reference pattern but does not make every stain specific (general IHC practice). |
| Isoforms and epitope | UniProt lists three ARHGEF9 isoforms (UniProt O43307). The supplied evidence gives no antibody epitope or isoform coverage, so staining cannot be assigned to a particular isoform from this pattern alone. |
| Topology and processing | ARHGEF9 has no transmembrane segment, signal peptide, propeptide, or reported processing into shorter chains in this record (UniProt O43307). A membrane outline or extracellular deposit is therefore not the expected reference pattern (UniProt O43307; HPA tissue IHC). |
| IF/ICC: where should signal localize? | HPA reports supported cytosolic localization in ICC-IF, while UniProt also lists the postsynaptic density (HPA subcellular ICC-IF; UniProt O43307). This is a localization answer only; the supplied evidence gives no IF/ICC protocol option. |
| Antigen retrieval evidence | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. |
| Situation | Likely cause | Next action |
|---|---|---|
| Cerebellar positive control is blank. | The reference reports medium Purkinje cell staining (HPA tissue IHC); absent signal may reflect a failed staining run or unavailable antigen, without identifying which (general IHC practice). | Confirm Purkinje cells are present, then check the antibody's IHC validation, detection reagents, and run controls (general IHC practice). |
| Nuclei dominate the stain. | Nuclear enrichment conflicts with the cytoplasmic reference localization (UniProt O43307; HPA subcellular ICC-IF). Nonspecific staining or detection background is possible (general IHC practice). | Review a no-primary section and whether cytoplasmic signal follows the expected cells and structures (general IHC practice; HPA tissue IHC). |
| Color appears in alveolar cells or lymph node germinal center cells. | Both populations are listed as not detected (HPA tissue IHC). Signal there may represent cross-reactivity or endogenous detection activity (general IHC practice). | Compare the same cell populations with no-primary and appropriate detection controls; avoid calling the whole tissue positive from unrelated cells (general IHC practice). |
| Background obscures the cytoplasm. | Diffuse color can arise from detection background, inadequate blocking, or excessive primary antibody (general IHC practice); HPA describes a cytoplasmic tissue pattern (HPA tissue IHC). | Inspect a no-primary control, then review blocking, washes, and the dilution specified for the IHC-validated antibody (general IHC practice). |
| A strong membrane outline replaces cytoplasmic staining. | ARHGEF9 lacks a transmembrane segment and is annotated in cytoplasm and postsynaptic density (UniProt O43307); an outline is discordant with the supplied localization. | Check whether the outline persists without primary antibody and compare it with cytoplasmic Purkinje cell staining in the same run (general IHC practice; HPA tissue IHC). |
| Two tissue sections give different apparent intensity. | HPA records medium staining in selected cells and not-detected or low staining in others (HPA tissue IHC). Differences may reflect which cells were sampled, alongside run variation (general IHC practice). | Score the named cell population and compartment in each section; compare staining only after checking controls and run conditions (general IHC practice; HPA tissue IHC). |
Experiment evidence
IHC & IF images showing ARHGEF9 staining
A06931-1 · IHCImmunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using ARHGEF9 Antibody. The picture on the right is blocked
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000131089-ARHGEF9/tissue/cerebral+cortex#imid_9022004
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000131089-ARHGEF9/tissue/colon#imid_9011362
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000131089-ARHGEF9/tissue/liver#imid_9011363
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000131089-ARHGEF9/tissue/kidney#imid_9011364
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA055291; green = ARHGEF9, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA055291; green = ARHGEF9, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARHGEF9 IHC & IF
🧪Run cerebellum first and score Purkinje cells for staining (HPA: Medium in Purkinje cells). Use esophagus squamous epithelium as a negative tissue (HPA: Not detected in squamous epithelial cells); on the cerebellum slide, compare Purkinje cells with adjacent cells for background, without assuming those cells are ARHGEF9-negative (HPA: Medium in Purkinje cells).
Positive control tissue: Adrenal gland (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARHGEF9 in A-431, U-251MG, NIH 3T3, with annotated localisation: Cytosol (supported) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and host- and isotype-matched controls; use an ARHGEF9 knockout or immunizing-peptide competition as a biological specificity control (standard IHC practice; A06931-1 caption: peptide block). Block endogenous peroxidase for chromogenic detection, and check neuronal autofluorescence if using IF (standard IHC/IF practice).
⚠️Feasibility: A target-specific fixation window and the effect of antigen retrieval are unreported in the supplied evidence; optimize retrieval empirically for paraffin sections (standard IHC practice). The selected A06931-1 paraffin-section caption leaves the fixative unreported (A06931-1 caption: paraffin-embedded lung carcinoma; fixative not stated). Frozen sections are not established as easier here; IF/ICC has supported cytosolic localization, but neuronal autofluorescence can complicate IF interpretation in cerebellum (HPA: Cytosol supported; HPA: cerebellum Purkinje cells Medium; standard IF practice).
HPA tissue IHC evidence for ARHGEF9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuropil | Medium | Protein (IHC) | HPA → |
| Colon | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARHGEF9 IHC Tips
Troubleshoot ARHGEF9 staining by checking retrieval, compartment, cell type and controls before interpreting differences in chromogenic signal.
How should I retrieve ARHGEF9 in paraffin sections when staining is weak?
Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 min (page retrieval specification). Cool sections consistently before blocking and applying the catalog antibody, and keep the heating vessel and section thickness consistent across comparison slides (standard IHC practice). If staining remains weak, compare a modestly longer citrate retrieval with the specified condition on adjacent sections, while checking for tissue damage or rising background (standard IHC practice). Use an appropriate cellular positive control: Purkinje cells and cerebral cortex neuropil have reported medium staining, whereas hippocampal glial cells were not detected (HPA tissue IHC).
Could fixation explain weak or uneven ARHGEF9 staining in paraffin sections?
ARHGEF9-specific sensitivity to fixative type or fixation duration is unknown from the supplied evidence; the selected product caption identifies paraffin sections but does not state a fixative (selected IHC caption, A06931-1). Record the actual fixative, time to fixation and fixation duration for each specimen before comparing staining intensity (standard IHC practice). When possible, stain similarly processed sections together using the specified citrate pH 6.0, 95–98 °C, 20 min retrieval (page retrieval specification). If one processing batch stains weakly, compare an independently processed cellular positive control and examine tissue preservation before assigning the difference to ARHGEF9 expression (standard IHC practice).
Where should convincing ARHGEF9 chromogenic signal appear?
Assess ARHGEF9 chiefly in the cytoplasmic compartment, while allowing a localized postsynaptic pattern where neuronal architecture can be resolved (UniProt O43307 subcellular annotation; HPA tissue IHC). Its sequence has no transmembrane segment, and its documented cellular location includes cytoplasm and postsynaptic density (UniProt O43307 topology and subcellular annotation). Compare staining within the relevant cell population: HPA reports medium signal in cerebellar Purkinje cells and cerebral cortex neuropil, but no detection in hippocampal glial cells (HPA tissue IHC). Predominantly nuclear or indiscriminate surface staining warrants comparison with negative controls and morphology before being scored as ARHGEF9 (UniProt O43307 subcellular annotation; standard IHC practice).
Could isoforms or epitope accessibility cause discordant ARHGEF9 IHC results?
ARHGEF9 has 3 annotated isoforms, but the supplied product caption does not map the catalog antibody’s epitope or establish isoform coverage (UniProt O43307 isoforms; selected IHC caption, A06931-1). The protein contains SH3 (8–67), DH (103–287) and PH (318–425) domains, plus a reported phosphoserine at 502 (UniProt O43307 domains and modified residues). Check the antibody’s documented immunogen or epitope before attributing discordant tissue staining to splice variation or phosphorylation (standard IHC practice). The selected paraffin-section image includes synthesized-peptide blocking, which supports a competition check for that image but does not by itself resolve isoform specificity (selected IHC caption, A06931-1; standard IHC interpretation).
How can IF help verify a disputed ARHGEF9 IHC pattern?
Use IF as a separate localization check and multiplex ARHGEF9 with a validated marker for the expected cell type, such as a Purkinje-cell marker when examining cerebellum (HPA tissue IHC; standard IF practice). Select a far-red fluorophore when tissue autofluorescence interferes with shorter-wavelength channels, and include single-stain controls to assess bleed-through (standard IF practice). Because ARHGEF9 is reported in the cytosol and postsynaptic density and lacks a transmembrane segment, assess gentle permeabilisation for intracellular access; the catalog antibody’s epitope position is not supplied (UniProt O43307 subcellular annotation and topology; selected IHC caption, A06931-1). Interpret IF alongside morphology and the chromogenic sections, since HPA reports supported cytosolic localization in its cellular imaging (HPA subcellular).
How do I reduce diffuse brown background without losing ARHGEF9 signal?
First inspect a no-primary control and a known low-signal cell population to distinguish detection background from the expected cytoplasmic pattern (standard IHC practice; HPA tissue IHC). For peroxidase-based chromogenic detection, include a peroxidase block before DAB development and check whether pigment or endogenous enzyme activity remains visible in controls (standard IHC practice). Titrate the catalog antibody and detection incubation against a positive tissue section, and use appropriate protein blocking and thorough washes if nonspecific staining is widespread (standard IHC practice). HPA reports no detection in lung alveolar cells and lymph-node germinal-center cells; evaluate those specific cells rather than treating whole sections as uniformly negative (HPA tissue IHC).
How should I quantify ARHGEF9 staining across paraffin specimens? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, because ARHGEF9 has reported cytoplasmic expression and tissue-dependent cellular patterns (HPA tissue IHC; UniProt O43307 subcellular annotation). For discrete cells, record percent positive and intensity grades 0–3, then calculate an H-score from 0–300; for diffuse neuropil, measure positive area or optical density within a defined region (standard IHC practice). Normalize cell counts to the number of eligible cells, or positive area to analyzed tissue area, and exclude necrosis, folds and section edges consistently (standard IHC practice). Keep retrieval, DAB development, imaging settings and thresholds matched across compared slides, and report the scoring compartment separately (standard IHC practice).
When is a brown ARHGEF9 pattern credible rather than artefactual?
A credible pattern follows the expected cytoplasmic or localized postsynaptic distribution and appears in an appropriate cell population, such as cerebellar Purkinje cells (UniProt O43307 subcellular annotation; HPA tissue IHC). Compare suspicious signal with no-primary and peroxidase-block controls, and inspect whether it concentrates at section edges, folds or necrotic areas (standard IHC practice). Predominantly nuclear staining or similarly intense signal across unrelated cells needs further verification; HPA reports no detection in lung alveolar cells despite the selected product image using human lung carcinoma tissue (UniProt O43307 subcellular annotation; HPA tissue IHC; selected IHC caption, A06931-1). Peptide blocking in that product image is useful supporting evidence for its staining pattern, but tissue identity and morphology still govern interpretation (selected IHC caption, A06931-1; standard IHC interpretation).
Boster reagents
Best ARHGEF9 / Rho guanine nucleotide exchange factor 9 IHC Antibodies
A06931-1 has a paraffin-section IHC image from human lung carcinoma tissue (catalog image caption). IF and ICC are listed applications, with Human, Mouse and Rat reactivity (catalog applications and reactivity).
Real IHC data
Anti-ARHGEF9/Collybistin Antibody
Cat # A06931-1
A06931-1 has an IHC image of paraffin-embedded human lung carcinoma tissue with peptide blocking shown (catalog image caption). IF and ICC are listed applications, and Human, Mouse and Rat are listed as reactive species; no IF image is supplied (catalog applications, reactivity and image records).
Which to pick: For tissue IHC, choose A06931-1: its image shows staining in a paraffin-embedded human lung carcinoma section (catalog image caption). For IF/ICC or work involving Human, Mouse or Rat samples, A06931-1 is the listed rabbit polyclonal option, though no IF image is supplied (catalog host, dilution record, applications, reactivity and image records). The IHC caption does not report the fixative (catalog image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O43307 (ARHG9_HUMAN, Rho guanine nucleotide exchange factor 9).
- Human Protein Atlas. ARHGEF9 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARHGEF9 subcellular location (ICC-IF): Localized to the cytosol..
- Human Protein Atlas. ARHGEF9 antibody validation summary (2 antibodies).
- Biochemical and Morphological Characterization of a Guanine Nucleotide Exchange Factor ARHGEF9 in Mouse Tissues. Acta histochemica et cytochemica 2018 — PMC6066644.
- PubMed PMID:9455477 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:15772651 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARHGEF9 (Rho guanine nucleotide exchange factor 9). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A06931-1 at 1:100 - 1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human lung carcinoma tissue; fixative not specified (datasheet A06931-1); 2. Fixation: Image fixative and duration unreported (datasheet A06931-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-ARHGEF9, 1:100 - 1:300 (datasheet A06931-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Hippocampal glial cells may be unstained (HPA tissue IHC); Isoform / epitope: 3 isoforms; epitope coverage is unspecified (UniProt; datasheet); Regulation: No staining-relevant regulation specified (UniProt). Evidence: UniProt O43307, HPA tissue IHC · Approved, HPA ICC-IF · cytosol., Datasheet A06931-1, PMC6066644. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARHGEF9/immunohistochemistry-ihc-guide.